MedTrace Logo

Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis

NCT01314495 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-11-14

No results posted yet for this study

Summary

Will Abatacept reduce priming of the hair follicle specific T cells and thereby reduce hair follicle associated infiltration and improve hair growth.

This is a double blind placebo controlled study to test the safety and efficacy of Abatacept in the treatment of 64 subjects diagnosed with alopecia totalis or alopecia universalis. Subjects will be randomized 1:1 to the placebo or treatment arm and will receive 6 months of treatment with the study medication or placebo, followed by a 6 month observational period.

Conditions

  • Alopecia Totalis/Universalis

Interventions

DRUG

Abatacept

Abatacept will be administrated as a 30 minute intravenous infusion.

DRUG

Inactive infusion

Placebo will be administered as a 30 minute intravenous infusion.

Sponsors & Collaborators

  • Julian M. Mackay-Wiggan

    lead OTHER

Principal Investigators

  • Julian Mackay-Wiggan, MD, MS · Columbia University

  • Angela Christiano, PhD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-06-30
Completion
2012-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01314495 on ClinicalTrials.gov